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PClopidogrel 600-Mg Double
Loading Dose Achieves Stronger
Platelet Inhibition Than Conventional Regimens
Results From the PREPAIR Randomized Study
Philippe L. L’Allier, MD, Grégory Ducrocq, MD, Nicolas Pranno, MD, Stéphane Noble, MD,
Reda Ibrahim, MD, Jean C. Grégoire, MD, Fabian Azzari, MD, Anna Nozza, MSC,
Colin Berry, MD, PHD, Serge Doucet, MD, Benoit Labarthe, PHARMD, Pierre Théroux, MD,
Jean-Claude Tardif, MD, for the PREPAIR Study Investigators
Montreal, Quebec, Canada
Objectives The objective of this study was to compare the level of platelet inhibition achieved by 3 different clopidogrel
loading regimens in patients undergoing elective angiography and percutaneous coronary intervention when ap-
propriate.
Background Optimal platelet inhibition is a key therapeutic goal for patients undergoing percutaneous coronary intervention.
Although 600 mg has been described as the maximum absorbed dose when given as a single bolus, the effects
of 2 boluses given 24 h apart have not been described.
Methods Patients (n  148) were randomly assigned to one of 3 regimens: Group A, clopidogrel 300 mg the day before
(15 h)  75 mg the morning of the procedure; Group B, clopidogrel 600 mg the morning of the procedure (2
h); and Group C, clopidogrel 600 mg the day before (15 h) and 600 mg the morning of the procedure (2 h).
Blood samples were obtained at baseline and immediately before angiography. Peak and late platelet aggrega-
tion were measured in platelet rich plasma, with researchers blinded to treatment allocation.
Results There was a consistent difference favoring Group C in all aggregation parameters. Percent inhibition in Groups A,
B, and C was 31.4%, 29.0%, and 49.5%, respectively, for peak aggregation (5 mol/l adenosine diphosphate; p
 0.0001) and 54.1%, 57.7%, and 81.1%, respectively, for late aggregation (p  0.0001). Similar striking re-
ductions were observed when 20 mol/l adenosine diphosphate was used. All comparisons between Group C
and the other 2 groups were statistically significant, and those between Groups A and B were not.
Conclusions Clopidogrel 600-mg double bolus achieves greater platelet inhibition than conventional single loading
doses. (J Am Coll Cardiol 2008;51:1066–72) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.013s
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6ptimal platelet inhibition is a key therapeutic goal for
atients undergoing percutaneous coronary intervention
PCI). The combination of aspirin plus clopidogrel cur-
ently represents the standard of care in this setting (1–3).
lopidogrel loading affords more rapid and more potent
latelet aggregation inhibition than the chronically admin-
stered dose (4). This better inhibition leads to clinical
enefits in the context of PCI (5,6) and is therefore
urrently recommended before interventions (1–3,7,8). Sin-
le loading doses up to 900 mg before PCI have failed to
rom the Department of Medicine, Montreal Heart Institute and Université de
ontréal, Montreal, Quebec, Canada. The PREPAIR study was funded by a grant
rom the Montreal Heart Institute Research Foundation, Montreal, Quebec, Canada.g
Manuscript received August 3, 2007; revised manuscript received November 23,
007, accepted December 2, 2007.how significantly greater platelet inhibition than the 600
g loading dose (7,8). This limitation may be due to limited
lopidogrel absorption (8), but time-dependent, cumulative
fficacy also has been suggested (9). Clopidogrel loading
oses of 600 mg at least 2 h before and 300 mg given at least
5 h before catheterization have been independently pro-
osed as optimal dosages but have not been directly com-
ared. In addition, the effects of 2 separate loading doses of
00 mg, given 18 to 24 h apart, have not been described.
herefore, the optimal clopidogrel loading dose remains
nknown. The main objective of this randomized study was
o compare the degree of platelet inhibition achieved by 3
ifferent clopidogrel loading regimens, including a double
00-mg loading dose in patients undergoing elective an-
iography and PCI when appropriate. Our hypothesis was
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March 18, 2008:1066–72 Clopidogrel Double Loading Dose Is Optimalhat a larger loading dose and optimal treatment duration
ould accelerate and potentiate the antiaggregatory effects
f clopidogrel.
ethods
atient population. The protocol was approved by the
nstitutional ethics committee, and patients gave written
nformed consent. Patients with suspected or documented
oronary artery disease admitted to our hospital for elective
oronary angiography and PCI when appropriate were
onsidered eligible. Patients with unstable angina, acute or
ecent (14 days) myocardial infarction; who were receiving
lycoprotein IIb/IIIa inhibitors; suffered a stroke within 3
onths; exhibited malignancies, active bleeding, or bleeding
iathesis; underwent oral anticoagulation with a coumarin
erivate or prothrombin time 1.5 times control; had
ecent treatment (30 days) with a GP IIb/IIIa antagonist
r thienopyridine; a platelet count100,000/mm3; a serum
reatinine 180 mmol/l; with severe liver disease resulting
n abnormal bilirubin levels; with a known allergic reaction
o thienopyridines (clopidogrel or ticlopidine); or had con-
omitant investigational drug use within 1 month were
xcluded.
tudy design. Patients were randomly assigned to 1 of 3
oading dose regimens according to an automated random-
zation list (1:1:1 ratio) provided by the Montreal Heart
nstitute Coordinating Center (Montreal, Canada) in sealed
nvelopes: Group A, clopidogrel 300 mg the day before
15 h)  75 mg the morning of the interventional
rocedure; Group B, clopidogrel 600 mg the morning of
2 h before) the interventional procedure; and Group C,
lopidogrel 600 mg the day before (15 h) and 600 mg the
orning of (2 h before) the interventional procedure.
lopidogrel loading doses were administered in an open
abel fashion by research nurses, but technicians performing
ggregation studies remained completely blinded to group
ssignment and did not have any direct contact with
atients. All stented patients received 75 mg of clopidogrel
aily for at least 30 days as clinically indicated after
mplantation. Blood was collected at the time of random-
zation (baseline), immediately before coronary angiogra-
hy, and the next morning (12 to 24 h) when a PCI was
erformed (post-PCI). All patients were examined for
omplications before hospital discharge and contacted by
elephone at 1 month to assess for adverse events. Diagnos-
ic and interventional procedures were performed according
o standard clinical practice.
ggregometry. Blood was collected from the forearm into
4.5-ml Vacutainer tubes containing 0.5 ml of sodium
itrate 3.2% (Becton Dickinson, Mississauga, Ontario,
anada). Platelet counts were measured with a Hematology
ystem ADVIA60 (Bayer Inc., Toronto, Ontario, Canada).
latelet-rich plasma (PRP) was prepared by centrifuging
lood for 10 min at 130 g. The remaining blood was further
entrifuged for 15 min at 1,800 g to prepare platelet-poor 0lasma (PPP). Platelet-rich plas-
a was adjusted to platelet counts
f 250,000 platelets/l by adding
PP as needed. Platelet aggrega-
ion was performed in stirred (135
) diluted PRP using a light trans-
ission aggregometer (Model
70VS, Chrono-Log Corpora-
ion, Havertown, Pennsylvania).
he PRP was used to set 0 light
ransmission and PPP to set 100
ight transmission. Platelet ag-
regation was systematically
easured after the addition of ADP at concentrations of 5
nd 20 mol/l (Sigma Chemical Co., Oakville, Ontario,
anada). Peak aggregation (Aggpeak) was measured at 1 to
min after the addition of the agonist, and late aggregation
Agg6min) was measured at 6 min, accounting then for
isaggregation (10). Percent inhibition of platelet aggrega-
ion was calculated as follows: (intensity of aggregation on
reatment  intensity of aggregation at baseline)/(intensity
f aggregation at baseline).
nd points. The primary end point of the study was the
ercent inhibition of Aggpeak at the time of angiography.
econdary end points included the percent inhibition of
gg6min; the percent inhibition of Aggpeak post-PCI; the
revalence of nonresponders (resistance) to clopidogrel us-
ng 3 definitions (10%, 20%, and 40% decrease in
ggpeak, respectively) (11–14); the occurrence of death,
yocardial infarction, or target vessel revascularization up to
0 days after procedure; and the occurrence of any of the
ollowing vascular or hemorrhagic complications: 1) major
leeding (defined as intracranial or clinically relevant bleed-
ng associated with a decrease in hemoglobin of5 g/dl); 2)
inor bleeding (clinically overt hemorrhage associated with
fall in hemoglobin 5 g/dl); 3) access-site complications
hematoma, pseudoaneurysm, or arteriovenous fistula); and
) thrombocytopenia with platelet count 70,000/mm3 or
ide effect requiring interruption of clopidogrel.
ample size calculation and statistical analysis. The pri-
ary assumption was that Group C regimen (600-mg
ouble loading dose) would increase inhibition of platelet
ggregation by at least 15% over that of Groups A and B.
he study had 80% power to evaluate this difference in
he primary end point with an alpha-level of 0.05 and 50
atients in each group, assuming a standard deviation of
5%. Continuous variables are expressed as mean  SD,
nd their differences were tested with a one-way analysis
f variance. Categorical variables are expressed as fre-
uencies and percentage; the chi-square test was used
nless otherwise indicated. The Fisher exact test was used
hen the row total was 10. A 1-way analysis of variance
as used to compare the inhibition of platelet aggrega-
ion among the 3 groups. All pairwise comparisons were
erformed only if the global F test was significant at the
Abbreviations
and Acronyms
ADP  adenosine
diphosphate
Aggpeak  peak
aggregation
Agg6min  late aggregation
PCI  percutaneous
coronary intervention
PPP  platelet-poor plasma
PRP  platelet-rich plasma.05 level. No adjustments were made to control for the
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Clopidogrel Double Loading Dose Is Optimal March 18, 2008:1066–72amily-wise error rate. A repeated measure analysis of
ovariance model, including baseline value, time (base-
ine, angiography, post-PCI), group (Group A, Group B,
roup C), and the interaction term (time*group), was
erformed to determine the post-PCI inhibition of
ggpeak. If the interaction term was significant at the
.05 level, then comparisons between groups at each time
oint were done. To quantify the changes between the
ime points, estimates were calculated to compare the groups
n the absolute changes between the 3 time points. The
hanges between the time points are represented as percentages
or clinical interpretation although the p values are calcu-
ated from the absolute changes. All analyses were done
ith SAS version 9.1 (SAS Institute Inc., Cary, North
arolina) and conducted at the 0.05 significance level.
esults
atient characteristics. The baseline characteristics of pa-
ients were well matched in the 3 study groups, except for
iabetes which was more frequent in Groups A and B
Table 1). Adjusting statistically for diabetes did not alter
ny of the results.
aseline Demographics
Table 1 Baseline Demographics
Group A (n  4
Age, mean (SD), yrs 61.8 (8.9)
Weight, mean (SD), kg 83.4 (18.7
Height, mean (SD), cm 166.3 (6.9)
Male, n (%) 41 (83.7
Risk factors, n (%)
Hypercholesterolemia 43 (87.8
Hypertension 38 (77.6
Current smoker 15 (30.6
Diabetes 15 (30.6
Family history of CAD 33 (67.4
History, n (%)
Myocardial infarction 15 (31.3
Coronary angioplasty 8 (16.7
Coronary bypass 7 (14.3
Procedure, n (%)
PCI 12 (25.5
Radial access 28 (59.6
Number of coronary vessels diseased, n (%)
0-vessel disease 10 (20.4
1-vessel disease 12 (24.5
2-vessel disease 10 (20.4
3-vessel disease 17 (34.7
Left ventricular ejection fraction, mean (SD) 61.2% (9.1)
Medications, n (%)
Aspirin* 48 (98.0
Statin 37 (78.7
Beta-blocker 34 (72.3
ACEI/ARA 30 (63.8
Calcium blocker 19 (40.4
Creatinine, mean (SD) mol·ml1 95 (23)Fisher exact test was used to test nonsignificance.
ACEI  angiotensin-converting enzyme inhibitor; ARA  angiotensin receptor agonist; CAD  coronaryain outcome. Percent inhibition of Aggpeak at the time
f angiography when platelets were stimulated with 5 or 20
mol/l ADP is illustrated in Figure 1. Inhibition of platelet
ggregation was consistently better in the clopidogrel 600
g double bolus group as compared with the other 2
egimens. Percent inhibition of Aggpeak was 31.4% in
roup A, 29.0% in Group B, and 49.5% in Group C (p 
.0001) when platelets were stimulated with 5 mol/l ADP
nd 22.4%, 22.3%, and 39.8%, respectively, with 20 mol/l
DP (p  0.0001). The Aggpeak values did not differ at
aseline (p  0.29 with 5 mol/l ADP and p  0.24 with
0 mol/l ADP) but were significantly different on treat-
ent (p  0.0001 with both 5 and 20 mol/l ADP) (Table
). Comparisons between Group C and other groups were
ighly significant (p  0.0002 vs. Group A, p  0.0001 vs.
roup B), and those between Groups A and B were not
p  0.62).
econdary outcomes. Percent inhibition of Agg6min re-
ults are illustrated in Figure 2. Late platelet aggregation
nhibition was also consistently stronger in the clopi-
ogrel 600 mg double bolus group as compared with the
ther 2 regimens. Percent inhibition of Agg6min was
Group B (n  49) Group C (n  50)
61.9 (8.9) 61.3 (9.7)
85.1 (16.0) 83.6 (17.5)
166.9 (8.3) 166.5 (8.6)
39 (79.6) 35 (70.0)
41 (83.7) 38 (76.0)
36 (73.5) 32 (64.0)
9 (18.4) 11 (22.0)
16 (33.3) 6 (12.2)
30 (61.2) 35 (70.0)
14 (29.2) 7 (14.0)
11 (22.5) 12 (24.5)
4 (8.2) 3 (6.0)
13 (27.1) 15 (30.0)
31 (66.0) 28 (56.0)
12 (24.5) 15 (30.0)
9 (18.4) 8 (16.0)
11 (22.5) 16 (32.0)
17 (34.7) 11 (22.0)
61.0% (8.8) 61.8% (5.3)
47 (95.9) 49 (98.0)
42 (87.5) 39 (78.0)
26 (54.2) 27 (54.0)
24 (50.0) 23 (46.0)
20 (41.7) 16 (32.0)
91 (22) 91 (15)9)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)artery disease; PCI  percutaneous coronary intervention.
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roup C when platelets were stimulated with 5 mol/l
DP (p  0.0001) and 36.7%, 40.5%, and 68.0%,
espectively, with 20 mol/l ADP (p  0.0001). Agg6min
alues did not differ at baseline (p  0.09 with 5 mol/l
DP and p  0.12 with 20 mol/l ADP) but were
ignificantly different on treatment (p  0.0001) (Table
). Comparisons between Group C and other groups
ere highly significant (p  0.0001 vs. Group A, p 
.0001 vs. Group B), and those between groups, A and B
ere not (p  0.50). The more potent platelet inhibition
bserved at the time of angiography in Group C was
aintained after PCI (n  36). Percent inhibition of
ost-PCI Aggpeak (20 mol/l ADP) was 21.0% in Group
, 28.4% in Group B, and 59.8% in Group C (p 
.0001 Group C vs. A; p  0.0005 Group C vs. B; p 
.25 Group A vs. B).
Interestingly, there were no nonresponders to clopi-
ogrel in Group C as compared with the other groups
sing 10% decrease in Aggpeak in response to 5 mol/l
Figure 1 Percent Inhibition of Peak Aggregation
Group A, clopidogrel 300 mg the day before (15 h)  75 mg the morning of
the interventional procedure; Group B, clopidogrel 600 mg the morning of (2
h before) the interventional procedure; Group C, clopidogrel 600 mg the day
before (15 h) and 600 mg the morning of (2 h before) the interventional
procedure. Significant differences between Groups A versus C and Groups B
versus C were found for 5 mol/l and 20 mol/l adenosine diphosphate (ADP)
(see text for details).
eak Aggregation Values
Table 2 Peak Aggregation Values
Group A
5 mol/l ADP
Baseline (SD) 61.0 (11.6)
Pre-angiography (SD) 41.3 (14.8)
20 mol/l ADP
Baseline (SD) 72.2 (8.5)
Pre-angiography (SD) 55.5 (14.6)
p  0.0002 for Group C versus A; p  0.0001 for Group C versus B; p  0.62 for Group B versus
; p  0.0001 for Group C versus B; p  0.97 for Group B versus A.
ADP  adenosine diphosphate.DP (9 in Group A, 8 in Group B and 0 in Group C, p
0.005). When using 20% or 40% decrease as
lternative definitions for nonresponsiveness, there re-
ained a highly significant advantage of the double bolus
egimen (Group C) as compared with the other 2 groups
p  0.001 and p  0.0002, respectively) (Fig. 3A).
imilarly striking results were seen when 20 mol/l ADP
as used (Fig. 3B).
afety. There was no death, rehospitalization for myocar-
ial infarction, or repeat target vessel revascularization up to
0 days. Post-PCI cardiac troponin T elevations 0.1 g/l
ere infrequent and equally distributed (2 [22%] in Group
, 2 [18%] in Group B and 3 [21%] in Group C, Fisher
xact p  1.0). There was no episode of major bleeding
uring 1 month follow-up. The incidence of minor bleeding
as low and similar in the 3 groups, although numerically
ore frequent in Group B (3 in Group A, 8 in Group B,
nd 4 in Group C, p 0.19) and mainly related to puncture
ites (e.g., ecchymosis, oozing, hematoma). Clopidogrel up
Figure 2 Percent Inhibition of Late Aggregation
Late platelet aggregation: 6 min after the addition of the agonist. Group A, clo-
pidogrel 300 mg the day before (15 h)  75 mg the morning of the interven-
tional procedure; Group B, clopidogrel 600 mg the morning of (2 h before)
the interventional procedure; Group C, clopidogrel 600 mg the day before (15
h) and 600 mg the morning of (2 h before) the interventional procedure. Sig-
nificant differences between Groups A versus C and Groups B versus C were
found for both for 5 and 20 mol/l adenosine diphosphate (ADP) (see text for
details).
oup B Group C p Value
8 (10.4) 58.3 (9.1) 0.29
7 (11.7) 29.6 (12.4)* 0.0001†
8 (7.1) 69.3 (8.7) 0.24
7 (13.5) 41.6 (14.9)‡ 0.0001†
lue is from a 1-way analysis of covariance adjusted for baseline. ‡p  0.0001 for Group C versusGr
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Clopidogrel Double Loading Dose Is Optimal March 18, 2008:1066–72o 600 mg twice within 18 to 24 h was otherwise well
olerated. No patient developed clinically evident allergy to
lopidogrel.
Figure 3 Clopidogrel Resistance
Data presented according to 3 definitions of resistance: 10%, 20%, and
40% decrease in peak platelet aggregation. (A) 5 mol/l ADP; (B) 20 mol/l
ADP. Group A, clopidogrel 300 mg the day before (15 h)  75 mg the morn-
ing of the interventional procedure; Group B, clopidogrel 600 mg the morning
of (2 h before) the interventional procedure; Group C, clopidogrel 600 mg the
day before (15 h) and 600 mg the morning of (2 h before) the interven-
tional procedure. Significant differences between Groups A versus C and
Groups B versus C were found for 5 mol/l and 20 mol/l adenosine diphos-
phate (see text for details).
ate Aggregation Values (6 Min)
Table 3 Late Aggregation Values (6 Min)
Group A
5 mol/l ADP
Baseline 55.4 (14.7)
Pre-angiography 25.2 (16.0)
20 mol/l ADP
Baseline 70.8 (9.0)
Pre-angiography 44.5 (19.5)
p  0.0001 for Group C versus A; p  0.0001 for Group C versus B; p  0.53 for Group B versus
; p  0.0001 for Group C versus B; p  0.53 for Group B versus A.
ADP  adenosine diphosphate.aiscussion
o our knowledge, this is the largest study to date compar-
ng clopidogrel loading regimens and the first to report the
ffects of a double bolus loading strategy before an inter-
entional procedure. Although other studies have compared
ncreasing loading doses (up to 900 mg) given as single
oluses only (7,8), the present study was specifically de-
igned to integrate the concepts of larger doses to accelerate
nd potentiate the antiaggregratory effects of clopidogrel
nd optimal treatment duration to benefit from time-
ependent, cumulative effects. The most striking finding in
his study is that a double bolus of 600 mg of clopidogrel
chieves more potent platelet inhibition than either clopi-
ogrel 600-mg single bolus or 300-mg single bolus 15 h
efore plus 75 mg the morning of an interventional proce-
ure. Another important finding is that clopidogrel 300-mg
ingle bolus given 15 h before plus 75 mg the morning of
n interventional procedure provides equivalent platelet
nhibition as a larger 600-mg single bolus given the morning
f the procedure (2 h).
The most likely explanation for the better platelet inhi-
ition achieved with a double bolus of clopidogrel lies in the
igher plasma concentrations of clopidogrel and its active
etabolite. von Beckerath et al. (8) have demonstrated that
oading with a single bolus of clopidogrel 600 mg resulted in
reater plasma concentrations of the active metabolite of
lopidogrel as compared with loading with a single bolus of
00 mg. In the same study, loading with clopidogrel
00-mg single bolus failed to increase further the plasma
oncentrations of the active metabolite of clopidogrel and its
nchanged form, strongly suggesting that intestinal absorp-
ion is the limiting step when single doses exceeding 600 mg
re administered. A strategy of 2 separate clopidogrel 600
g doses at 18- to 24-h interval would likely circumvent
his limiting step and allow more absorption of the drug.
iven that clopidogrel is an inactive prodrug that requires to
e metabolized to an active compound and provided that
he metabolism of clopidogrel does not become saturated,
he double bolus strategy can be expected to achieve better
nhibition of platelet aggregation, as was the case in this
tudy. More specifically, a greater concentration of the
p B Group C p Value
13.0) 49.1 (13.9) 0.09
14.5) 10.4 (13.8)* 0.0001†
7.5) 67.0 (9.9) 0.12
20.3) 22.1 (20.4)‡ 0.0001†
lue is from a 1-way analysis of covariance adjusted for baseline. ‡p  0.0001 for Group C versusGrou
51.2 (
20.8 (
69.3 (
41.1 (
A. †p vactive metabolite could lead to a more complete saturation
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March 18, 2008:1066–72 Clopidogrel Double Loading Dose Is Optimalf the P2Y12 receptors, which appears very partial at
tandard clopidogrel doses (15). In addition, if the circulat-
ng levels are high enough, it is not completely impossible
hat other platelet receptors be blocked concomitantly (e.g.,
2Y1), further inhibiting aggregation.
Interestingly, our results highlight a time-dependent
atch-up phenomenon after a 300-mg loading dose as
ompared with the 600-mg loading dose. Previous studies
ave convincingly demonstrated a more rapid and some-
hat more potent inhibition of platelet aggregation when
00 mg of clopidogrel was compared with 300 mg during
he first 24 h (12,16). However, these studies have not
escribed the peak level of inhibition achieved when loading
oses were administered at different intervals before inter-
ention. Groups A and B in the current study did not differ
n terms of the intensity of the inhibition of platelet
ggregation at the time of the angiography despite a loading
ose twice as large. The main difference between the
espective regimens of both groups (in addition to the
osages) was the timing of the administration of the loading
ose (15 h vs. 2 h). It is possible that although the peak
evel of active clopidogrel metabolite reached after 300-mg
as lower than with 600 mg, the length of exposure might
ave compensated if the clearance of the active metabolite is
lower than previously described (8). The effect of the
dditional 75-mg dose the morning of the intervention
ight also have played a role to potentiate to the inhibitory
ffect of the 300-mg loading dose on the existing platelets or
y inhibiting the platelets produced by the bone marrow in
he interim. Therefore, a more modest loading dose given
arly enough (e.g., 15 h) could be equivalent to a larger
oading dose given shortly before PCI.
The importance of nonresponsiveness (resistance) to
lopidogrel may be underestimated clinically. Indeed, an
ncreased level of inhibition in patients that would not have
therwise achieved an adequate response with standard
osing may have a larger impact than a further increase in
hose with an already adequate response. Many data now
uggest that a poor response to clopidogrel is associated with
ncreased event rates (13,14,17–21). Recently, Patti et al.
22) demonstrated that pretreatment with a 600-mg loading
ose of clopidogrel reduced periprocedural myocardial in-
arctions by one-half in patients undergoing PCI when
ompared with a 300-mg loading dose. Buonamici et al.
23) identified nonresponsiveness to clopidogrel in vitro as a
trong independent predictor of stent thrombosis in patients
eceiving drug-eluting stents. Furthermore, Bliden et al.
24) showed that patients undergoing nonemergent PCI
ho exhibit high ADP-induced platelet aggregation while
eing treated with clopidogrel are at increased risk for
ost-procedural ischemic events. The absence of nonre-
ponders to clopidogrel when using the 600-mg double
oading strategy in the present study suggests that this may
epresent a clinically relevant finding. Because we identified
 clopidogrel loading regimen that achieves stronger platelet
nhibition and decreases the proportion of nonrespondersithout apparently increasing bleeding, it is indeed reason-
ble to expect reductions in clinical events. However, larger
tudies are needed to confirm the clinical impact of this
ouble loading dose. The hypothesis that stronger platelet
nhibition is associated with better outcomes is now being
ested with P2Y12 receptor blockers, both thienopyridines
nd nonthienopyridines. If this hypothesis is demonstrated
fficacious and safe, the double loading dose as used in this
tudy would become of even greater interest given the well
ocumented efficacy of clopidogrel in large clinical trials.
ntil then, the double loading dose approach could be used
n the large number of patients referred for coronary
ngiography and ad hoc PCI from other hospitals or as
utpatient.
tudy limitations. There are limitations to this study.
irst, open-label administration of clopidogrel was used.
ecause the primary end point was not clinical and all
aboratory analyses were performed with researchers blinded
o treatment assignments, no impact on the primary end
oint is expected. Second, the study was underpowered to
etect meaningful differences in clinical events.
onclusions
clopidogrel 600-mg double loading dose (first dose given
ore than 15 h before and second dose given the morning
f an interventional procedure) achieves greater platelet
nhibition than conventional single loading doses. Clopi-
ogrel administered as a 300-mg single bolus given 15 h
rior to plus 75 mg on the morning of an intervention
chieves equivalent platelet inhibition as a 600-mg single
olus loading dose given on the morning of the procedure.
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